Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla

Stopped early · Phase 2

Conditions studied: Ductal Adenocarcinoma of Pancreas, Adenocarcinoma of Ampulla

In brief

Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free survival at 1 yr from initiation of treatment.

Key facts

Study ID

NCT02626520

Run by

Essentia Health

People needed

11

Starts

2016-05-11

Expected to finish

2017-09-14

Last updated by the study team

2018-11-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic proof of adenocarcinoma consistent with ductal carcinoma of pancreas or ampulla, with no evidence of metastatic disease by clinical exam or cross-sectional imaging.
• Fitness for chemotherapy in judgement of treating physician
• Bilirubin < 4 (any means of biliary drainage acceptable)

You may not qualify if…

• Medical or mental illness precluding provision of informed consent
• Pregnancy
• Active infection for which neutropenia would pose high risk of mortality

Where it is running

• Essentia Health Cancer Center — Duluth, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.